The effect of almitrine bismesylate on hypoxemia in chronic obstructive pulmonary disease patients living at moderate altitude

John W Bloom, S. Campbell, Stuart F Quan, B. Y. Shon

Research output: Contribution to journalArticle

Abstract

The effect of almitrine bismesylate on hypoxemia was investigated in a placebo-controlled, double-blind study of 39 patients with chronic obstructive pulmonary disease living at moderate altitude (1,500-6,597 feet) above sea level. Arterial partial oxygen pressure (PO2) increased by 5.3 mmHg (P < 0.05) in patients receiving 50 mg twice daily and by 7.1 mmHg (P < 0.05) in patients receiving 100 mg twice daily. Arterial partial carbon dioxide pressure (PCO2) decreased (P < 0.05) in both dose groups and minute ventilation increased in the 100-mg twice-daily group (P < 0.05). However, the change in arterial PCO2 was small compared with the increase in arterial PO2. Almitrine bismesylate was well tolerated by patients in this study with unexplained worsening of dyspnea occurring in only one patient. Therefore, almitrine bismesylate appears to be a useful agent for relieving hypoxemia in patients with chronic obstructive pulmonary disease living at moderate altitude.

Original languageEnglish (US)
Pages (from-to)327-334
Number of pages8
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume43
Issue number2
StatePublished - 1988

Fingerprint

Almitrine
Chronic Obstructive Pulmonary Disease
Partial Pressure
Double-Blind Method
Carbon Dioxide
Oceans and Seas
Dyspnea
Ventilation
Hypoxia
Placebos
Oxygen
Pressure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{7d342bfe308b4ba398b187dbfb9d2a1e,
title = "The effect of almitrine bismesylate on hypoxemia in chronic obstructive pulmonary disease patients living at moderate altitude",
abstract = "The effect of almitrine bismesylate on hypoxemia was investigated in a placebo-controlled, double-blind study of 39 patients with chronic obstructive pulmonary disease living at moderate altitude (1,500-6,597 feet) above sea level. Arterial partial oxygen pressure (PO2) increased by 5.3 mmHg (P < 0.05) in patients receiving 50 mg twice daily and by 7.1 mmHg (P < 0.05) in patients receiving 100 mg twice daily. Arterial partial carbon dioxide pressure (PCO2) decreased (P < 0.05) in both dose groups and minute ventilation increased in the 100-mg twice-daily group (P < 0.05). However, the change in arterial PCO2 was small compared with the increase in arterial PO2. Almitrine bismesylate was well tolerated by patients in this study with unexplained worsening of dyspnea occurring in only one patient. Therefore, almitrine bismesylate appears to be a useful agent for relieving hypoxemia in patients with chronic obstructive pulmonary disease living at moderate altitude.",
author = "Bloom, {John W} and S. Campbell and Quan, {Stuart F} and Shon, {B. Y.}",
year = "1988",
language = "English (US)",
volume = "43",
pages = "327--334",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "2",

}

TY - JOUR

T1 - The effect of almitrine bismesylate on hypoxemia in chronic obstructive pulmonary disease patients living at moderate altitude

AU - Bloom, John W

AU - Campbell, S.

AU - Quan, Stuart F

AU - Shon, B. Y.

PY - 1988

Y1 - 1988

N2 - The effect of almitrine bismesylate on hypoxemia was investigated in a placebo-controlled, double-blind study of 39 patients with chronic obstructive pulmonary disease living at moderate altitude (1,500-6,597 feet) above sea level. Arterial partial oxygen pressure (PO2) increased by 5.3 mmHg (P < 0.05) in patients receiving 50 mg twice daily and by 7.1 mmHg (P < 0.05) in patients receiving 100 mg twice daily. Arterial partial carbon dioxide pressure (PCO2) decreased (P < 0.05) in both dose groups and minute ventilation increased in the 100-mg twice-daily group (P < 0.05). However, the change in arterial PCO2 was small compared with the increase in arterial PO2. Almitrine bismesylate was well tolerated by patients in this study with unexplained worsening of dyspnea occurring in only one patient. Therefore, almitrine bismesylate appears to be a useful agent for relieving hypoxemia in patients with chronic obstructive pulmonary disease living at moderate altitude.

AB - The effect of almitrine bismesylate on hypoxemia was investigated in a placebo-controlled, double-blind study of 39 patients with chronic obstructive pulmonary disease living at moderate altitude (1,500-6,597 feet) above sea level. Arterial partial oxygen pressure (PO2) increased by 5.3 mmHg (P < 0.05) in patients receiving 50 mg twice daily and by 7.1 mmHg (P < 0.05) in patients receiving 100 mg twice daily. Arterial partial carbon dioxide pressure (PCO2) decreased (P < 0.05) in both dose groups and minute ventilation increased in the 100-mg twice-daily group (P < 0.05). However, the change in arterial PCO2 was small compared with the increase in arterial PO2. Almitrine bismesylate was well tolerated by patients in this study with unexplained worsening of dyspnea occurring in only one patient. Therefore, almitrine bismesylate appears to be a useful agent for relieving hypoxemia in patients with chronic obstructive pulmonary disease living at moderate altitude.

UR - http://www.scopus.com/inward/record.url?scp=0023840290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023840290&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023840290

VL - 43

SP - 327

EP - 334

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 2

ER -